What Is the Optimal Duration of Adjuvant Therapy in Colon Cancer? 

Anthony F. Shields, MD, PhD

  H&O  Which patients with colon cancer require adjuvant therapy? AS  Patients who are considered to be at high risk for recurrence require adjuvant therapy. This […]

From Recent Issues

The Value in Cancer Care Consortium: Addressing Financial Toxicity

  H&O  What is the Value in Cancer Care Consortium? AL  The Value in Cancer Care Consortium is a group of physicians who have come together […]

The Next Frontier in Non–Small Cell Lung Cancer: Synergizing Radiation Therapy and Immune Checkpoint Blockade

  Abstract: Immune checkpoint blockade (ICB), which harnesses the body’s immune system to recognize and kill cancer cells, has transformed the management landscape for patients with […]

Highlights in Breast Cancer From the 2017 American Society of Clinical Oncology Annual Meeting

  June 2-6, 2017 • Chicago, Illinois Subset of Patients With Heavily Pretreated Metastatic TNBC Respond to Pembrolizumab A subset of patients with heavily pretreated metastatic triple-negative […]

Supplements

Highlights in Lymphoma From the 2017 American Society of Clinical Oncology Annual Meeting and the 14th International Conference on Malignant Lymphoma

Supplement 11 A Review of Selected Presentations From the 2017 ASCO Annual Meeting • June 2-6, 2017 • Chicago, Illinois and the 14th ICML • June […]

Frontline Management of Chronic Lymphocytic Leukemia

Supplement 10 How I Treat Chronic Lymphocytic Leukemia: An Expert Perspective on Frontline Management Richard R. Furman, MD Director of the CLL Research Center Weill Cornell […]

Highlights in Aggressive Non-Hodgkin Lymphoma From the 2017 American Society of Clinical Oncology Annual Meeting

Supplement 8 A Review of Selected Presentations From the 2017 American Society of Clinical Oncology Annual Meeting • June 1-5, 2017 • Chicago, Illinois Clinical and […]